Contribute Try STAT+ Today

In a blow to Allergan (AGN), the U.S. Supreme Court rebuffed its effort to shield patents on a best-selling drug from a review board by transferring them to a Native American tribe.

The court left intact a ruling last July by a federal appeals court that upheld the ability of the U.S. Patent Trial and Appeal Board to decide whether a half-dozen patents for the Restasis eye treatment were valid. Allergan had argued that, under federal law, the sovereign status of the Saint Regis Mohawk Tribe meant that the patents were immune from review by the patent board.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The observation that this was “an erosion” is like calling a burst dam “just a leak?”

Comments are closed.